These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 20621731)

  • 21. 5-(1,3-Benzothiazol-6-yl)-4-(4-methyl-1,3-thiazol-2-yl)-1H-imidazole derivatives as potent and selective transforming growth factor-β type I receptor inhibitors.
    Amada H; Sekiguchi Y; Ono N; Koami T; Takayama T; Yabuuchi T; Katakai H; Ikeda A; Aoki M; Naruse T; Wada R; Nozoe A; Sato M
    Bioorg Med Chem; 2012 Dec; 20(24):7128-38. PubMed ID: 23117174
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Synthesis and biological evaluation of 1-(6-methylpyridin-2-yl)-5-(quinoxalin-6-yl)-1,2,3-triazoles as transforming growth factor-β type 1 receptor kinase inhibitors.
    Li F; Park Y; Hah JM; Ryu JS
    Bioorg Med Chem Lett; 2013 Feb; 23(4):1083-6. PubMed ID: 23294702
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Optimization of a dihydropyrrolopyrazole series of transforming growth factor-beta type I receptor kinase domain inhibitors: discovery of an orally bioavailable transforming growth factor-beta receptor type I inhibitor as antitumor agent.
    Li HY; McMillen WT; Heap CR; McCann DJ; Yan L; Campbell RM; Mundla SR; King CH; Dierks EA; Anderson BD; Britt KS; Huss KL; Voss MD; Wang Y; Clawson DK; Yingling JM; Sawyer JS
    J Med Chem; 2008 Apr; 51(7):2302-6. PubMed ID: 18314943
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Novel and potent transforming growth factor beta type I receptor kinase domain inhibitor: 7-amino 4-(2-pyridin-2-yl-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)-quinolines.
    Li HY; Wang Y; Yan L; Campbell RM; Anderson BD; Wagner JR; Yingling JM
    Bioorg Med Chem Lett; 2004 Jul; 14(13):3585-8. PubMed ID: 15177480
    [TBL] [Abstract][Full Text] [Related]  

  • 25. ALK5 kinase inhibitory activity and synthesis of 2,3,4-substituted 5,5-dimethyl-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazoles.
    Řezníčková E; Tenora L; Pospíšilová P; Galeta J; Jorda R; Berka K; Majer P; Potáček M; Kryštof V
    Eur J Med Chem; 2017 Feb; 127():632-642. PubMed ID: 28135685
    [TBL] [Abstract][Full Text] [Related]  

  • 26. 2-Aminoimidazoles inhibitors of TGF-beta receptor 1.
    Bonafoux D; Chuaqui C; Boriack-Sjodin PA; Fitch C; Hankins G; Josiah S; Black C; Hetu G; Ling L; Lee WC
    Bioorg Med Chem Lett; 2009 Feb; 19(3):912-6. PubMed ID: 19135364
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Discovery of N-((4-([1,2,4]triazolo[1,5-a]pyridin-6-yl)-5-(6-methylpyridin-2-yl)-1H-imidazol-2-yl)methyl)-2-fluoroaniline (EW-7197): a highly potent, selective, and orally bioavailable inhibitor of TGF-β type I receptor kinase as cancer immunotherapeutic/antifibrotic agent.
    Jin CH; Krishnaiah M; Sreenu D; Subrahmanyam VB; Rao KS; Lee HJ; Park SJ; Park HJ; Lee K; Sheen YY; Kim DK
    J Med Chem; 2014 May; 57(10):4213-38. PubMed ID: 24786585
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Application of Pd-Catalyzed Cross-Coupling Reactions in the Synthesis of 5,5-Dimethyl-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazoles that Inhibit ALK5 Kinase.
    Tenora L; Galeta J; Řezníčková E; Kryštof V; Potáček M
    J Org Chem; 2016 Dec; 81(23):11841-11856. PubMed ID: 27934472
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Design, synthesis, and evaluation of indolinones as inhibitors of the transforming growth factor β receptor I (TGFβRI).
    Roth GJ; Heckel A; Brandl T; Grauert M; Hoerer S; Kley JT; Schnapp G; Baum P; Mennerich D; Schnapp A; Park JE
    J Med Chem; 2010 Oct; 53(20):7287-95. PubMed ID: 20919678
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Synthesis and biological evaluation of 5-substituted 1,4-dihydroindeno[1,2-c]pyrazoles as multitargeted receptor tyrosine kinase inhibitors.
    Akritopoulou-Zanze I; Albert DH; Bousquet PF; Cunha GA; Harris CM; Moskey M; Dinges J; Stewart KD; Sowin TJ
    Bioorg Med Chem Lett; 2007 Jun; 17(11):3136-40. PubMed ID: 17391959
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Design and synthesis of novel 3,4-disubstituted pyrazoles for nanomedicine applications against malignant gliomas.
    Comes Franchini M; Bonini BF; Camaggi CM; Gentili D; Pession A; Rani M; Strocchi E
    Eur J Med Chem; 2010 May; 45(5):2024-33. PubMed ID: 20129719
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Inhibition of ALK5 as a new approach to treat liver fibrotic diseases.
    de Gouville AC; Huet S
    Drug News Perspect; 2006 Mar; 19(2):85-90. PubMed ID: 16628263
    [TBL] [Abstract][Full Text] [Related]  

  • 33. SD-208, a novel transforming growth factor beta receptor I kinase inhibitor, inhibits growth and invasiveness and enhances immunogenicity of murine and human glioma cells in vitro and in vivo.
    Uhl M; Aulwurm S; Wischhusen J; Weiler M; Ma JY; Almirez R; Mangadu R; Liu YW; Platten M; Herrlinger U; Murphy A; Wong DH; Wick W; Higgins LS; Weller M
    Cancer Res; 2004 Nov; 64(21):7954-61. PubMed ID: 15520202
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Rapid generation of a high quality lead for transforming growth factor-beta (TGF-beta) type I receptor (ALK5).
    Goldberg FW; Ward RA; Powell SJ; Debreczeni JE; Norman RA; Roberts NJ; Dishington AP; Gingell HJ; Wickson KF; Roberts AL
    J Med Chem; 2009 Dec; 52(23):7901-5. PubMed ID: 19736928
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Design, synthesis and optimization of 7-substituted-pyrazolo[4,3-b]pyridine ALK5 (activin receptor-like kinase 5) inhibitors.
    Sabat M; Wang H; Scorah N; Lawson JD; Atienza J; Kamran R; Hixon MS; Dougan DR
    Bioorg Med Chem Lett; 2017 May; 27(9):1955-1961. PubMed ID: 28359790
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacophore modeling and virtual screening for the discovery of new transforming growth factor-beta type I receptor (ALK5) inhibitors.
    Ren JX; Li LL; Zou J; Yang L; Yang JL; Yang SY
    Eur J Med Chem; 2009 Nov; 44(11):4259-65. PubMed ID: 19640613
    [TBL] [Abstract][Full Text] [Related]  

  • 37. SB-505124 is a selective inhibitor of transforming growth factor-beta type I receptors ALK4, ALK5, and ALK7.
    DaCosta Byfield S; Major C; Laping NJ; Roberts AB
    Mol Pharmacol; 2004 Mar; 65(3):744-52. PubMed ID: 14978253
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Inhibition of RhoA/Rho-kinase pathway suppresses the expression of type I collagen induced by TGF-beta2 in human retinal pigment epithelial cells.
    Itoh Y; Kimoto K; Imaizumi M; Nakatsuka K
    Exp Eye Res; 2007 Mar; 84(3):464-72. PubMed ID: 17217948
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Inhibition of gene markers of fibrosis with a novel inhibitor of transforming growth factor-beta type I receptor kinase in puromycin-induced nephritis.
    Grygielko ET; Martin WM; Tweed C; Thornton P; Harling J; Brooks DP; Laping NJ
    J Pharmacol Exp Ther; 2005 Jun; 313(3):943-51. PubMed ID: 15769863
    [TBL] [Abstract][Full Text] [Related]  

  • 40. 7-[1H-Indol-2-yl]-2,3-dihydro-isoindol-1-ones as dual Aurora-A/VEGF-R2 kinase inhibitors: design, synthesis, and biological activity.
    Hughes TV; Emanuel SL; O'Grady HR; Connolly PJ; Rugg C; Fuentes-Pesquera AR; Karnachi P; Alexander R; Middleton SA
    Bioorg Med Chem Lett; 2008 Sep; 18(18):5130-3. PubMed ID: 18718756
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.